Long-term Impact of a “3 + 0” Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002–2014

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Infectious Diseases

• Publication date

  2017-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/cid/ciw720PMID 27986682
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pneumococcal conjugate vaccine herd effects on non-invasive pneumococcal pneumonia in elderly.

  2016cited by this paper
• Retrospective economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Australia: Uncertain herd impact on pneumonia critical.

  2016cited by this paper
• Long term population impact of seven-valent pneumococcal conjugate vaccine with a "3+0″ schedule-How do "2+1″ and "3+1″ schedules compare?

  2015cited by this paper
• Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.

  2015cited by this paper
• Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.

  2015influential reference
• Invasive pneumococcal disease in Australia, 2009 and 2010.

  2015cited by this paper
• Ebola: the real lessons from HIV scale-up.

  2015cited by this paper
• Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.

  2015influential reference
• Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children.

  2015cited by this paper
• Ebola: the real lessons from HIV scale-up.

  2015cited by this paper
• [Effects of vaccination on invasive pneumococcal disease in South Africa].

  2015cited by this paper
• Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.

  2015cited by this paper
• Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia

  2015cited by this paper
• ‘The Australian Immunisation Handbook 8th Edition’. National Health and Medical Research Council, Australian Government. Canberra: Commonwealth of Australia; 2003. 350 pages, ISBN 0-642-82204-2

  2015cited by this paper
• Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis.

  2014cited by this paper
• Effects of vaccination on invasive pneumococcal disease in South Africa.

  2014cited by this paper
• Trends in Asymptomatic Nasopharyngeal Colonization With Streptococcus pneumoniae After Introduction of the 13-valent Pneumococcal Conjugate Vaccine in Calgary, Canada

  2014cited by this paper
• Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study.

  2014cited by this paper
• Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial.

  2013influential reference
• Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.

  2013cited by this paper
• Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia.

  2013cited by this paper
• Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites

  2013cited by this paper
• Optimizing the use of pneumococcal conjugate vaccine globally.

  2013cited by this paper
• Systematic Review of the Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Vaccine-type Nasopharyngeal Carriage

  2013cited by this paper
• Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.

  2012cited by this paper
• Effect of vaccines on bacterial meningitis worldwide.

  2012cited by this paper
• Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England

  2012cited by this paper
• The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial.

  2012cited by this paper
• Pneumococcal vaccines WHO position paper--2012.

  2012cited by this paper
• Long term trends introduce a potential bias when evaluating the impact of the pneumococcal conjugate vaccination programme in England and Wales.

  2011cited by this paper
• Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study.

  2011cited by this paper
• Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine.

  2011cited by this paper
• Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis.

  2011cited by this paper
• Reduction in Hospitalizations for Pneumonia Associated With the Introduction of a Pneumococcal Conjugate Vaccination Schedule Without a Booster Dose in Australia

  2010influential reference
• Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers

  2010cited by this paper
• Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers

  2010cited by this paper
• Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.

  2010cited by this paper
• The Australian Childhood Immunisation Register-A model for universal immunisation registers?

  2009cited by this paper
• Pneumococcal Serotypes and Mortality following Invasive Pneumococcal Disease: A Population-Based Cohort Study

  2009cited by this paper
• The Impact of Pneumococcal Conjugate Vaccine on Rates of Myringotomy With Ventilation Tube Insertion in Australia

  2009cited by this paper
• Epidemiological differences among pneumococcal serotypes.

  2005cited by this paper
• The Australian Immunisation Handbook

  2000cited by this paper
• Pneumococcal vaccines. WHO position paper.

  1999cited by this paper

• Clinical effectiveness and impact of 13-valent pneumococcal conjugate vaccines in preventing invasive pneumococcal disease among children with risk conditions: A systematic literature review

  2026cites this paper
• Invasive pneumococcal disease in children with acute lymphoblastic leukaemia

  2026cites this paper
• Risk Groups for Vaccine-Preventable Respiratory Infections in Children and Adults: An Overview of the Australian Environment

  2025cites this paper
• Effectiveness of vaccine dosing schedules for pneumococcal invasive disease in children: A systematic review and meta-analysis

  2025cites this paper
• Immunization information systems’ implementation and characteristics across the world: a systematic review of the literature

  2025cites this paper
• Global distribution and characteristics of pneumococcal serotypes in adults

  2025cites this paper
• Impact of pneumococcal conjugate vaccination on pneumococcal nasopharyngeal carriage in the Gambia: Population-based cross-sectional surveys

  2024cites this paper
• Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development

  2024cites this paper
• Assessing the Impact of Pneumococcal Conjugate Vaccine Immunization Schedule Change From 3+0 to 2+1 in Australian Children: A Retrospective Observational Study.

  2024cites this paper
• Effects of PCV10 and PCV13 on pneumococcal serotype 6C disease, carriage, and antimicrobial resistance.

  2024cites this paper
• Evaluation of the direct and indirect impact on pneumonia hospitalization after almost a decade of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Brazil

  2023cites this paper
• A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age

  2023cites this paper
• The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C

  2023cites this paper
• Coverage of 13-Valent Pneumococcal Conjugate Vaccine Among Children 0–15 Months of Age — 9 Provinces, China, 2019–2021

  2023cites this paper
• Effectiveness of COVID-19 Vaccination Against SARS-CoV-2 Omicron Variant Infection and Symptoms — China, December 2022–February 2023

  2023cites this paper
• Predictors of pneumococcal vaccination among Australian adults at high risk of pneumococcal disease.

  2022cites this paper
• Changing Trends of Invasive Pneumococcal Disease in the Era of Conjugate Pneumococcal Vaccination in Olmsted County: A Population-Based Study.

  2022cites this paper
• Waning of antibody levels induced by a 13-valent pneumococcal conjugate vaccine, using a 3 + 0 schedule, within the first year of life among children younger than 5 years in Blantyre, Malawi: an observational, population-level, serosurveillance study

  2022cites this paper
• Kinetics of pneumococcal antibodies among HIV-exposed, uninfected infants in Botswana.

  2022cites this paper
• Pneumococcal conjugate vaccination schedules in infants—acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study

  2022cites this paper
• Vaccination with LytA, LytC, or Pce of Streptococcus pneumoniae Protects against Sepsis by Inducing IgGs That Activate the Complement System

  2021cites this paper
• Assessing the impact of the 13 valent pneumococcal vaccine on childhood empyema in Australia

  2021cites this paper
• A cluster-randomised, non-inferiority trial of the impact of a two-dose compared to three-dose schedule of pneumococcal conjugate vaccination in rural Gambia: the PVS trial

  2021cites this paper
• Pneumococcal Immunization Strategies for High-Risk Pediatric Populations Worldwide: One Size Does Not Fit All

  2021cites this paper
• Estimating the risk of recurrent invasive pneumococcal disease in Australia, 1991-2016.

  2021cites this paper
• Levels of pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: An observational study

  2021cites this paper
• Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance

  2021cites this paper
• Pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: a retrospective record linkage cohort study

  2021cites this paper
• Streptococcus Pneumoniae septic arthritis in adults in Bristol and Bath, United Kingdom, 2006–2018: a 13-year retrospective observational cohort study

  2021cites this paper
• A pragmatic health centre-based evaluation comparing the effectiveness of a PCV13 schedule change from 3+0 to 2+1 in a high pneumococcal carriage and disease burden setting in Malawi: a study protocol

  2021cites this paper
• Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia

  2021cites this paper
• 10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised

  2020cites this paper
• Early Impact of 13-valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease among Adults with and without Underlying Medical Conditions-United States.

  2020cites this paper
• Clinical Effectiveness of Conjugate Pneumococcal Vaccination In Hematopoietic Stem Cell Transplant Recipients.

  2020cites this paper
• Characteristics of invasive pneumococcal disease (IPD) caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in England; prospective observational cohort study, 2014-18.

  2020cites this paper
• Paediatric empyema: worsening disease severity and challenges identifying patients at increased risk of repeat intervention

  2020cites this paper
• Vacunación frente a la enfermedad neumocócica con vacunas conjugadas: ¿qué es lo que verdaderamente importa?

  2020cites this paper
• High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi

  2020cites this paper
• Incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate pneumococcal vaccine in British Columbia: A retrospective cohort study

  2020cites this paper
• Nationwide trends of invasive pneumococcal disease in Spain (2009-2019) in children and adults during the pneumococcal conjugate vaccine era.

  2020cites this paper
• Paediatric pneumonia in high-income countries: Defining and recognising cases at increased risk of severe disease.

  2020cites this paper
• Trends in Bacteremia Over 2 Decades in the Top End of the Northern Territory of Australia

  2020cites this paper
• Vaccination with conjugate vaccines against pneumococcal disease: What really matters

  2020cites this paper
• Vaccine strategies to reduce the burden of pneumococcal disease in HIV-infected adults in Africa.

  2020cites this paper
• The impact of the changing pneumococcal national immunisation program among older Australians.

  2020cites this paper
• Impact of 10-Valent Pneumococcal Conjugate Vaccine Introduction on Pneumococcal Carriage and Antibiotic Susceptibility Patterns Among Children Aged <5 Years and Adults With Human Immunodeficiency Virus Infection: Kenya, 2009–2013

  2019cites this paper
• Persistence of pneumococcal antibodies after primary immunisation with a polysaccharide–protein conjugate vaccine

  2019cites this paper
• Control and prevention of invasive pneumococcal disease in Taiwan: Current achievements and future challenges.

  2019cites this paper
• Summary of national surveillance data on vaccine preventable diseases in Australia, 2012-2015.

  2019cites this paper
• Increasing Rates of Pediatric Empyema and Disease Severity With Predominance of Serotype 3 S. pneumonia: An Australian Single-Center, Retrospective Cohort 2011 to 2018.

  2019cites this paper
• Invasive Pneumococcal Disease in Children’s Hospitals: 2014–2017

  2019cites this paper
• Vaccine Preventable Diseases and Vaccination Coverage in Aboriginal and Torres Strait Islander People, Australia, 2011–2015

  2019cites this paper
• Long-term Vaccine Impact on Invasive Pneumococcal Disease Among Children With Significant Comorbidities in a Large Australian Birth Cohort.

  2019cites this paper
• To boost or not to boost? Lessons from the Australian pneumococcal conjugate vaccination program.

  2019cites this paper
• Long-term impact of pneumococcal conjugate vaccines on invasive disease and pneumonia hospitalisations in Indigenous and non-Indigenous Australians.

  2019cites this paper
• Meningitis vaccines in children: what have we achieved and where next?

  2019cites this paper
• Persistence of immunity to conjugate and polysaccharide pneumococcal vaccines in frail, hospitalised older adults in long-term follow up.

  2019cites this paper
• A National Review of Vaccine Preventable Diseases in Australia

  2019cites this paper
• Immunisation

  2019cites this paper
• A rationale for change: an increase in Invasive Pneumococcal Disease in fully vaccinated children.

  2019cites this paper
• Smart Scheduling - optimising national immunisation programmes to achieve maximum impact.

  2019cites this paper
• Impact of Childhood Pneumococcal Conjugate Vaccine on Nonnotified Clinically Suspected Invasive Pneumococcal Disease in Australia.

  2019cites this paper
• Change in Pneumococcus Serotypes but not Mortality or Morbidity in Pre- and Post-13-Valent Polysaccharide Conjugate Vaccine Era: Epidemiology in a Pediatric Intensive Care Unit over 10 Years

  2018cites this paper
• Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule Without a Booster Dose: A 10-Year Observational Study

  2018cites this paper
• High residual vaccine-serotype Streptococcus pneumoniae carriage 4 to 6 years after the introduction of 13-valent pneumococcal conjugate vaccine in Malawi: a prospective serial cross-sectional study

  2018cites this paper
• Impact of pneumococcal conjugate vaccines introduction on antibiotic resistance of Streptococcus pneumoniae meningitis in children aged 5 years or younger, Israel, 2004 to 2016

  2018cites this paper
• Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution

  2018cites this paper
• Pneumococcal vaccination in older persons: where are we today?

  2018influential citation
• Continued occurrence of serotype 1 pneumococcal meningitis in two regions located in the meningitis belt in Ghana five years after introduction of 13-valent pneumococcal conjugate vaccine

  2018cites this paper
• Determining the pneumococcal conjugate vaccine coverage required for indirect protection against vaccine-type pneumococcal carriage in low and middle-income countries: a protocol for a prospective observational study

  2018cites this paper
• A toddler PCV booster dose following 3 infancy priming doses increases circulating serotype-specific IGG levels but does not increase protection against carriage.

  2018cites this paper
• Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.

  2018cites this paper
• Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study.

  2018cites this paper
• Bacterial-Host Interactions: Physiology and Pathophysiology of Respiratory Infection.

  2018cites this paper
• The Alere BinaxNOW Pneumococcal Urinary Antigen Test: Diagnostic Sensitivity for Adult Pneumococcal Pneumonia and Relationship to Specific Serotypes

  2017cites this paper
• Impact of pneumococcal conjugate vaccines for children in high- and non–high-income countries

  2017cites this paper
• A new paradigm in pneumococcal conjugate vaccination: moving from individual to herd protection.

  2017cites this paper
• Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies.

  2017cites this paper
• Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial

  2017cites this paper
• Enhancing preparedness for tackling new epidemic threats

  2017cites this paper
• Predictors of pneumococcal carriage and the effect of the 13-valent pneumococcal conjugate vaccination in the Western Australian Aboriginal population

  2017cites this paper
• The future of paediatric pneumococcal conjugate vaccines.

  2017cites this paper